Akari Therapeutics (AKTX)
(Delayed Data from NSDQ)
$3.19 USD
-0.16 (-4.64%)
Updated Aug 15, 2024 03:12 PM ET
After-Market: $3.17 -0.02 (-0.47%) 6:22 PM ET
3-Hold of 5 3
D Value B Growth NA Momentum NA VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AKTX 3.19 -0.16(-4.64%)
Will AKTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AKTX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for AKTX
12 Health Care Stocks Moving In Tuesday's Intraday Session
Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders
Akari Therapeutics announces interm CEO employment contract
Akari Therapeutics announces interm CEO employment contract
Akari Therapeutics Secures $7.6 Million in Upsized Financing Round